Cellmax Ret Software Testing
CellMax Life’s Precision, Non-Invasive Cancer Testing Now Available throughout Southeast Asia through Asia Genomics. CellMax and Asia Genomics Enter Broad Partnership to Serve South-East Asia Singapore and Sunnyvale, CA, July 12, 2017 — Asia Genomics, Southeast Asia’s leading clinical laboratory is partnering with Silicon Valley-based CellMax Life to immediately introduce CellMax Life’s multi-biomarker precision oncology tests blood and saliva tests across Southeast Asia. The advanced diagnostic testing will reduce cancer mortality through personalized, precision cancer risk assessment and screening in the Philippines, Vietnam, Malaysia, Thailand, and Singapore.
Affordable Precision Testing Gives Individuals Achieve More Control According to the GLOBOCAN database, the ratio of cancer deaths to the number of new cancer cases in Asia was 0.66, twice that of North America (0.33). Only in Africa were cancer patients more likely to die (0.73). This an indication that cancer is not diagnosed until later stages in Asia, when it becomes difficult to treat effectively. Individuals and their families no longer need to be passive about their health in the face of these risks — the Asia Genomics and CellMax Life partnership will give everyone more control over their health. Asia Genomics will immediately make available CellMax Life’s affordable personalized and precision cancer risk assessment and screening through various hospitals and clinics throughout Southeast Asia, and, where appropriate, direct to consumer. Individuals can now achieve the earliest possible cancer detection and treatment by assessing their risk of cancer and doing more frequent screening through the non-invasive blood tests, so that they can undertake timely measures if cancer is diagnosed.
CellMax develops and markets ultra high power efficiency base. Find RET controller software. (these results also can also be proven by drive test. CMA-RET RET, AISG The CellMax RET consists of a stepper motor that can be connected to the rotating axis used for adjusting the electrical down-tilt of CellMax RET.
In a complementary manner, Oncologists using the non-invasive blood tests will be able to more accurately assess the risk of cancer relapse, and offer personalized treatments to patients. Next Generation Techniques Deliver Affordable, Precision Cancer Testing The CellMax tests uniquely combine proprietary and clinically proven CTC and CtDNA technologies that have been tested in Asia: 1.CellMax-DNA Genetic Cancer Risk Test Assure — a simple saliva DNA test to identify hereditary cancer risk. The test provides an affordable and accessible saliva test to identify an individual’s cancer pre-disposition, to help them preempt worst case scenarios.
It examines 98 genes across 25 hereditary cancers — currently the broadest gene panel on the market — offering highest quality, fastest turnaround time and affordable price. The largest possible number of individuals and families can for the first time better understand their risk of cancer, and then work with their doctors for a customized screening and lifestyle plan. Hereditary gene mutations can increase the risk of cancer by 20 times. Gas Dynamics 3rd Edition Pdf.